CHANGMAO BIO Secures RMB93.00 Million Ten-Year Syndicated Loan to Refinance Existing Project Debt

Bulletin Express
11/09

Hong Kong – Changmao Biochemical Engineering Company Limited (CHANGMAO BIO) announced that its wholly owned subsidiary, Changmao (Dalian) New Material Company Limited, has entered into a New Loan Agreement on 9 November 2026 with Industrial and Commercial Bank of China (ICBC) and Shanghai Pudong Development Bank (SPD). The facility will refinance the remaining RMB93.00 million of Project Loan II, converting short-term project debt into a long-term liability.

Key terms of the New Bank Loan • Facility size: RMB93.00 million • Drawdown deadline: On or before 31 October 2027; proceeds dedicated to full repayment of Project Loan II • Tenor & amortisation: 20 equal semi-annual instalments over 10 years, starting April 2027. Instalments escalate from RMB1.80 million (first ten payments) to RMB12.46 million in the final tranche. • Pricing: 5-year+ Loan Prime Rate (LPR) minus 50 basis points, reset annually. • Security package: (1) Industrial land and 30 buildings owned by Changmao Dalian (Certificate No. Liao (2021) Dalian Changxingdao Real Estate No. 06900014) and (2) property and land held by Shanghai Changmao Biochemical Engineering Company Limited. • Guarantee: Full corporate guarantee from CHANGMAO BIO. • Financial covenants: The lenders may accelerate repayment if (i) consolidated annual net operating cash flow turns negative, or (ii) year-end debt-to-asset ratio exceeds 65%.

Balance-sheet implications The new 10-year facility replaces the remaining 93.00 million in short-term project debt, extending the maturity profile and supporting liquidity. Following the refinancing, the Group retains a separate Project Loan with an outstanding balance of RMB48.75 million.

Counterparties ICBC (Changzhou and Dalian branches) and SPD (Changzhou branch) are the lending institutions. Both banks are PRC-incorporated and listed on the Shanghai Stock Exchange. The company confirms that the lenders and their ultimate beneficial owners are independent third parties.

Strategic rationale Management expects the refinancing to strengthen the Group’s capital structure by reducing near-term repayment pressure and aligning debt service with long-term cash-flow generation from its organic acid production operations.

Board confirmation The Board, chaired by Mr Rui Xin Sheng, approved the transaction, asserting that the extended maturity better positions CHANGMAO BIO to manage its financing needs over the next decade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10